Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phenoxybenzamine is a non-selective, irreversible alpha-adrenergic antagonist used primarily to manage and treat hypertension and excessive sweating associated with pheochromocytoma, a tumor of the adrenal gland. It works by covalently binding to both alpha-1 and alpha-2 adrenergic receptors, leading to long-lasting blockade of these receptors. This action causes vasodilation by relaxing vascular smooth muscle, resulting in lowered blood pressure. Phenoxybenzamine is administered orally and has a prolonged duration of effect due to its irreversible receptor binding[1][2][3][5][6]. The drug does not affect the parasympathetic system.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phenoxybenzamine.